Scribe Therapeutics vs Grok
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $100M Series B. Jennifer Doudna co-founder. Sanofi + Eli Lilly partnerships. STX-1150 (PCSK9 silencing via CasX-ELXR) IND projected mid-2026 — no permanent DNA edits.
About
Scribe Therapeutics was co-founded by Jennifer Doudna — who shared the 2020 Nobel Prize in Chemistry for CRISPR-Cas9 invention — and develops the ELXR platform: a CasX-based epigenetic silencing system that reduces gene expression without making permanent DNA cuts. The company has raised $100 million in Series B financing with strategic partnerships with Sanofi and Eli Lilly. The lead program, STX-1150, targets PCSK9 for durable LDL-C reduction and is projected to receive an IND and enter human trials in mid-2026.
AI assistant by xAI (Elon Musk); Grok 3 topped reasoning benchmarks in Feb 2025; 1M+ paying subscribers in week one; real-time X post access; distributed via X Premium; xAI valued at $24B.
About
Grok is the AI assistant developed by xAI, Elon Musk's AI company founded in 2023, and distributed primarily through X (formerly Twitter). Grok launched in November 2023 as an X Premium perk, with the notable differentiator of real-time access to X posts and a less restricted, more direct conversational style. Grok 3, released in February 2025, achieved top scores on the AIME math reasoning benchmark and ARC-AGI test, briefly positioning xAI as a frontier model lab.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.